Adalimumab biosimilar - Celltrion

Drug Profile

Adalimumab biosimilar - Celltrion

Alternative Names: CT-P17

Latest Information Update: 14 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celltrion
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Eye disorder therapies; Skin disorder therapies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Rheumatoid arthritis

Most Recent Events

  • 07 Aug 2018 Celltrion files an Clinical Trial Authorisation (CTA) application with the Medicine and Healthcare Products Regulatory Agency (MHRA) in the UK for Rheumatoid arthritis
  • 07 Aug 2018 Celltrion plans a global phase III trial for Rheumatoid arthritis in 8 nations in the Europe in August 2018
  • 07 Aug 2018 Celltrion plans a phase I trial for safety and pharmacokinetic assessment of adalimumab biosimilar in United Kingdom in August 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top